검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ZM-02 (low dose) |
Overview Company | Zhongmou Therapeutics |
Overview Modality | CGT |
Overview Target | Retinitis Pigmentosa (RP) |
Overview Indication | Retinitis Pigmentosa (RP) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin pathway |
MoA Biomarker | biomarkers such as BRCA mutations and homologous recombination deficiency (HRD) |
PK/PD Species | Mouse, xenografts, co-administrat |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, xenografts, co-administrat |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Use of low-dose immune checkpoint inhibitors in low- and middle-income countries: a national survey of oncologists and hematologists in Mexico.. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for multiple cancers but remain largely inaccessible in low- and middle-income countries (LMICs) due to high costs and limited availability. Pharmacokinetic and pharmacodynamic d… |
Clinical Primary efficacy | ORR 14.2% |
Clinical ORR | 14.2% |
Clinical Result source | ClinicalTrials.gov NCT04592419 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ZM-02 (low dose) |
Overview Company | Zhongmou Therapeutics |
Overview Modality | CGT |
Overview Target | Retinitis Pigmentosa (RP) |
Overview Indication | Retinitis Pigmentosa (RP) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin pathway |
MoA Biomarker | biomarkers such as BRCA mutations and homologous recombination deficiency (HRD) |
PK/PD Species | Mouse, xenografts, co-administrat |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, xenografts, co-administrat |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Use of low-dose immune checkpoint inhibitors in low- and middle-income countries: a national survey of oncologists and hematologists in Mexico.. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for multiple cancers but remain largely inaccessible in low- and middle-income countries (LMICs) due to high costs and limited availability. Pharmacokinetic and pharmacodynamic d… |
Clinical Primary efficacy | ORR 14.2% |
Clinical ORR | 14.2% |
Clinical Result source | ClinicalTrials.gov NCT04592419 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교